Sigrid Therapeutics has announced the publication of a study in mice in the journal Nanomedicine demonstrating the enzyme-blocking effects of mesoporous silica particles (MSPs) introduced to the gut and the
Nordic Life Science
NLS Pharma News
Pharma
University of Virginia (UVA) Center for Diabetes Technology and Novo Nordisk have announced that they have entered into a five-year research collaboration. The two collaborators will work together on the
AstraZeneca’s Lynparza regulatory submission granted Priority Review in the US for 1st-line maintenance treatment with bevacizumab in advanced ovarian cancer. AstraZeneca and MSD have announced that a supplemental New Drug
Spago Nanomedical has appointed lead compound in the Tumorad project and is now proceeding development into pre-clinical proof-of-concept validation in tumor models. ”Nomination of lead compound is an important step
This dual listing will further enable the advance its two innovative programs: CDNF in Parkinson’s Disease and drug candidate, Lymfactin, in Lymphedema. As part of the offering Herantis issued a
Nanoform has filed for GMP status with the Finnish Medicines Agency, FIMEA. The drug substance application for GMP clinical manufacture certification exemplifies its progress and growth in the last 12
Clinical trials
Following the recommendation from an independent Data Monitoring Committee, AstraZeneca has decided to close the Phase III STRENGTH trial for Epanova (omega-3
NeuroVive Pharmaceutical has announced the completed recruitment of healthy volunteers in the second part of the company’s ongoing Phase Ia/b
Immunovia has announced that the Commercial Test Model study was successful, showing a 95% accuracy, and the company is on
BerGenBio has provided an update from the company’s phase II study of bemcentinib (BGB324), an oral AXL inhibitor, in combination
The first patient has been successfully dosed in the Phase I study with the wholly owned 4-1BB antibody ATOR-1017, which
Gedea Biotech has announced that all patients have been recruited for the multi-center study evaluating the clinical performance of an
Follicum has announced that data from studies on human Langerhans islets have shown positive effects on insulin release in line
Cantargia has announced that its research platform CANxx has progressed with the start of a drug development project, CAN10. The
BioArctic has announced that data from the ongoing BAN2401 Phase 2b open-label extension study in early Alzheimer’s disease patients was
Monday December 9th, Moberg Pharma announced results from the first study in the Phase 3 program for MOB-015, where the
Trastuzumab deruxtecan achieved a tumour response rate of 60.9% in the Phase II HER2-positive metastatic breast cancer trial. AstraZeneca and
LINK Medical has announced that it will carry out a pivotal phase III clinical trial on behalf of Sedana Medical,
Oncopeptides has presented updated data from its ongoing Phase 2 ANCHOR (OP-104) triple combination study. In the data presented at
GeNeuro has announced a collaboration for a new clinical trial of temelimab in multiple sclerosis (MS) with clinical researchers of
Scandinavian Biopharma reports successful results of the ETEC vaccine candidate ETVAX in a placebo-controlled phase I/II study in infants and
Follicum has announced that the company has signed a collaboration agreement with proDERM for conducting the new clinical trial with
Profiles in Pharma
BioArctic’s lead compound has the potential to become the first disease-modifying treatment for Alzheimer’s, and so far the company’s journey
Few companies are as synonymous with Sweden as AstraZeneca and few CEOs as visible. Yet, Katarina Ageborg, AstraZeneca Sweden’s new
She joined LEO Pharma by chance, more than 27 years ago, but she remained there, for the true focus on
“It is with great regret and sadness we announce this very tragic and unexpected information,” says the Board of Directors,
In an interview in Nordic Life Science, the Head of AstraZeneca’s Oncology Business unit, shared his insights on current drug
Ironically, there is less serendipity in the success Saeid Esmaeilzadeh and Ashkan Pouya have achieved as business-makers than there is
Logistics
With a deadline looming to meet a new EU Falsification Medicines Directive (FMD) by 2019, there is no shortage of challenges for packaging experts. Besides satisfying EU requirements, drug manufacturers
Packaging is an often overlooked element of the life science supply chain but the industry needs to step up quality and foster innovation in order to keep up with developments